Enhanced potency of daunorubicin against multidrug resistant subline KB-Ch(R)-8-5-11 by a pulsed magnetic field

Anticancer Research

Volumn 17, Issue 3 C, 1997, Pages 2083-2088

  Liang, Yayun ^a,b   Hannan Jr , Charles J ^a,b   Chang, Barbara K ^a,b,c   Schoenlein, Patricia V ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Athymic (nude) mice; Daunorubicin; Drug resistance; Experimental therapeutics; Pulsed magnetic fields; Tumor models

Indexed keywords

DAUNORUBICIN; GLYCOPROTEIN P; RHODAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CARCINOMA CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MAGNETIC FIELD; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; CLONE CELLS; COMBINED MODALITY THERAPY; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; KB CELLS; MAGNETICS; MICE; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030796179     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Boring CC, Squires TS, Tong T and Montgomerg S: Cancer statistics, 1994. CA 44: 7-26, 1994.
2. Petrini M, Mattii L, Sahbatini A, Carulli G, Grassi B: Multidrug resistance and electromagnetic fields. J Bioelec 9: 209-212, 1990.
3. Omote Y, Hosokawa M, Komastsumoto M, Namieno T, Nakjima S, Kubo Y, Kobayashi H: Treatment of experimental tumors with a combination of a pulsing magnetic field and an Anti-tumor Drug. Jpn J Cancer Res 81: 956-961, 1990.
4. Cadossi R, Zucchini P, Emilia G et al: Effect of low frequency low energy pulsing electromagnetic fields on mice injected with cyclophosphamide. Exp Hematol 19: 196-201, 1991.
5. Salvetore JR, Blackington D, Wanebo H et al: Low-frequency magnetic fields as an adjunct to antineoplastic chemotherapy in a human breast carcinoma cell line. Proceedings of the 15th Annual Meeting of the Bioelectromagnetics Society, 126-127 (abstract), 1993.
6. Hannan CJ, Liang Y, Allison JD, Searle JR: In vitro cytotoxicity against human cancer cell lines during pulsed magnetic field exposure. Anticancer Res. 14: 1517-1520, 1994.
7. Hannan CJ, Liang Y, Allison JD, Pantazis CG, Searle JR: Chemotherapy of human carcinoma xenografts auring pulsed magnetic field exposure. Anticancer Res. 14: 1521-1524, 1994.
8. Hannan CJ, Liang Y, Chang BK, and Shelton WW: Potentiation of Daunorubicin cytoioxicity by a 60 HZ magnetic field. Proceedings of the 1994 International Symposium on Charge and Field Effects in Biosystems 4: 218-222, 1996.
9. Tenforde TS: Cellular and molecular pathways of extremely low frequency electromagnetic field interactions with living systems, In: Electricity and Magnetism in Biology and Medicine (Blank M, editor). San Francisco, San Francisco Press, Inc., 1993, pp 1-8.
10. Adey WR: Biological effects of electromagnetic fields. J Cellular Biochem 51: 410-416, 1993.
11. Goodman R, Chizmadzhev Y, Shirley-Henderson A: Electromagnetic fields and cells. J Cellular Biochem 57: 436-441, 1993.
12. Bruggemann EP, Germann UA, Gottesman MM, Pastan I: Two different regions of P-glycoprotein are photoaffinity-labeled by Azidopine. J Biol Chem 264: 15483-15488, 1993.
13. Ganapathi R, Hercbergs A, Grabowski D, Ford J: Selective enhancement of vincristine cytotoxicity in multidrug-resistant tumor cells by dilantin (phenytoin). Cancer Res 53: 3262-3265, 1993.
14. Arao S, Suwa G, Mandai M, Tashiro H, Miyazaki K, Okamura H, Nomura H, Hiai H, Fukumoto M: Expression of multidrug resistance gene and localization of p-glycoprotein in human primary ovarian cancer. Cancer Res 54: 1355-9, 1994.
15. Leyland-Jones B, Dalton W, Fisher GA, Sikic BI: Reversal of multidrug resistance to cancer chemotherapy. Cancer Supplement 72: 3484-3488, 1993.
16. Nielsen D, Maare C, Skovsgaard T: Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of p-glycoprotein. Biochem Pharmacol 47: 2125-2135, 1994.
17. Ramachandran D, Yuan ZK, Huang XL, Krishan A: Doxorubicin resistance in human melanoma cell: MDR-1 and Glutathione S-transferase genes expression. Biochem Pharmacol 45: 743-751, 1993.
18. Schoenlein PV, Shen D-W, Barrett JT, Pastan I, Gottesman MM: Double minute chromosomes carrying the human multidrug resistance 1 and 2 gene are generated from the dimerization of submicroscopic circular DNAs in colchicine-selected KB carcinoma cells. Mol Biol of the Cell 3: 507-520, 1992.
19. Akiyama SI, Fojo A, Hanover JA, Pastan I, Gottesman MM: Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somatic Cell Mol Genet 11: 117-126, 1985.
20. Shen D-W, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I, Gottesman MM: Human multidrug-resistant cell lines: increased mdrl expression can precede gene amplification. Science 232: 643-656, 1986.
21. Akiyama S-I, Pastan I, Gottesman MM: Isolation of human cell lines resistant to multiple drugs. J Cell Biol 97: 218a, 1983.
22. Thiebaut F, Hanauske AR, Von Hoff DD: Evidence for binding of extrachromosomal DNA sequences to nuclear matrix proteins in multidrug-resistant KB-V1 cells. FEBS 319: 133-137, 1993.
23. Fojo A, Akiyama S-I, Gottesman MM, Pastan I: Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res 45: 3002-3007, 1985.
24. Hannan CJ, Schoenlein PV, Liang Y, Wrenn R.W: Magnetic fields and Drugs Resistance. Submitted to FASEB J.
25. Hannan CJ, Liang Y, Schoenlein PV, Wrenn RW, Chang BK, Shelton WW: Magnetic, not electric field inhibition of multidrug resistance. Proceedings of the American Association for Cancer Research 36: 345, 1995.
26. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT et al: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Caner Inst 82: 1107-1112, 1990.
27. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S et al: Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82: 1113-1118, 1990.
28. Chou J, Chou T-C: Dose-effect analysis with microcomputers (version 2.0), Cambridge, England: Elsevier-BIOSOFT, 1986.
29. Chou T-C and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regula 22: 27-55, 1984.
30. Rutherford AV, Willingham MC: Ultrastructural localization of daunomycin in multidrug-resistant cultured cells with modulation of the multidrug transporter. J Histochem Cytochem 41: 1573-1577, 1993.
31. Egorin MJ, Hildebrand RC, Cimino EF, Bachur NR: Cytofluorescence localization of adriamycin and daunorubicin. Cancer Res 34: 22-43, 1974.
32. Willingham MC, Cornwell MM, Cardarelli CO, Gottesman MM, Pastan I: Single cell analysis of daunomycin uptake and afflux in multidrug resistant and sensitive KB cells: effects of verapamil and other drugs. Cancer Res 46: 5941-5946, 1986.
33. Chauffert B, Martin F, Caignard A, Jeannin JF, Leclerc A: Cytofluorescence localization of adriamycin in resistant colon cancer cells. Cancer Chemother Pharmacol 13: 14, 1984.
34. Inaba M, Kobayashi H, Sakurai Y, Johnson RK: Active efflux of daunomycin and adriamycin sensitive and resistant sublines of P388 leukemia. Cancer Res. 39: 2200-2203, 1979.
35. Kang Y, Perry RR: Effect of a-interferon on P-glycoprotein expression and function and on verapamil modulation of doxorubicin resistance. Cancer Res 54: 2952-2958, 1994.
36. Ford JM, Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacal Rev 42: 155-199, 1990.
37. Byus CV, Kartun K, Pieper SE et al: Increased ornithine decarboxylase activity in cultured cells exposed to low energy modulated microwave fields and phorbol ester tumor promoters. Cancer Res 48: 4222-4226, 1988.
38. Byus CV, Pieper SE, Adey WR: The effects of low energy 60 Hz environmental electromagnetic fields upon the growth-related enzyme ornithine decarboxylase. Carcinogenesis 8: 1385-1389, 1987.
39. Litovitz TA, Krause D, Penatiel M et al: The role of coherence time in the effect of microwaves on ornithine decarboxylase activity. Bioelectromagnetics 14: 395-403, 1993.
40. Litovitz TA, Krause D, Mullins JM: Effect of coherence time of the applied magnetic field on ornithine decarboxylase activity. Biochem Biophys Res Commun 178: 862-865, 1991.
41. Chang BK, Shelton WW: Ornithine decarboxylase activity in pancreatic cancer cells exposed to 60 Hz magnetic fields. Proceedings of the 15th Annual Meeting of the Bioelectromagnetics Society, Los Angeles, CA: 152 (abstract), 1993.
42. Timmer-Bosscha H, Mulder NH, de Vries EGE: Modulation of cis diamminedichloroplatinum (II) resistance: a review. Br J Cancer 66: 227-238, 1992.
43. Carson JJ, Prato FS, Drost DJ, Diesbourg LD, Dison SJ: Time-varying magnetic fields increase cytosolic free Ca in HL-60 cells. Am J Physiol 259: C687-C692, 1990.
44. Liburdy RP: Calcium signaling in lymphocytes and ELF fields. FEBS Lett 301: 53-59, 1992.
45. Phillips JL, Winters WD, Rutledge L: In vitro exposure to electromagnetic fields: change in tumor cell properties. Int J Radiat Biol 49: 463-496, 1986.